CompletedPHASE1, PHASE2NCT00118326
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease
Studying MITF-related melanoma and renal cell carcinoma predisposition syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Ann E. Woolfrey, MDFred Hutchinson Cancer Center
- Intervention
- filgrastim(biological)
- Eligibility
- 18 years · All sexes
- Timeline
- 2003 – 2007
Study locations (2)
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00118326 on ClinicalTrials.govOther trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).Merck Sharp & Dohme LLC
- RECRUITINGPHASE3NCT05078047Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IOUNICANCER
- ACTIVE NOT RECRUITINGPHASE1NCT04707248A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsDaiichi Sankyo
- RECRUITINGNCT05785052Biomarkers of Renal CancerBiorek S.R.L.
- ACTIVE NOT RECRUITINGPHASE1NCT03170960Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsExelixis
- RECRUITINGNCT00001238Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersNational Cancer Institute (NCI)
See all trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome →